Compound class:
Endogenous peptide in human, mouse or rat
Comment: CXCL10 is a C-X-C motif chemokine preferentially expressed by Th1 lymphocytes. It exerts its biological effects via interaction with the CXCR3 GPCR.
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| CXCL10 expression is induced by IFN-γ, and is produced by leukocytes, activated neutrophils, eosinophils, monocytes, epithelial cells, endothelial cells, stromal cells (fibroblasts) and keratinocytes under the proinflammatory effect of IFN-γ. CXCL10 expression is associated with the Th1 immune response and leukocyte homing to inflamed tissues, and this results in exacerbated inflammation and tissue damage [3]. It is also a chemoattractant for monocytes and NK cells. In humans, CXCL10 has been shown to be involved in the pathological processes underlying infectious diseases, inflammatory and autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome and systemic sclerosis) [3], and cancer. CXCL10 also has anti-angiogenesic activity which confers anti-tumor effects. |
